Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior.

Sahin IH, Elias H, Chou JF, Capanu M, O'Reilly EM.

BMC Cancer. 2018 Jul 28;18(1):769. doi: 10.1186/s12885-018-4679-9.

2.

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.

Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK.

Cancer Chemother Pharmacol. 2018 Sep;82(3):429-440. doi: 10.1007/s00280-018-3635-3. Epub 2018 Jul 3.

PMID:
29971467
3.

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.

Glassman DC, Palmaira RL, Covington CM, Desai AM, Ku GY, Li J, Harding JJ, Varghese AM, O'Reilly EM, Yu KH.

BMC Cancer. 2018 Jun 27;18(1):693. doi: 10.1186/s12885-018-4605-1.

4.

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK.

Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.

PMID:
29848569
5.

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D.

J Clin Oncol. 2018 Aug 20;36(24):2545-2556. doi: 10.1200/JCO.2018.78.9636. Epub 2018 May 23.

PMID:
29791286
6.

Classification of Pancreatic Cancer: Ready for Practical Application?

Khalil DN, O'Reilly EM.

Clin Cancer Res. 2018 Sep 15;24(18):4355-4356. doi: 10.1158/1078-0432.CCR-18-1113. Epub 2018 May 11.

PMID:
29752276
7.

A Randomized Trial of Acceptability and Effects of Values-Based Advance Care Planning in Outpatient Oncology: Person-Centered Oncologic Care and Choices.

Epstein AS, O'Reilly EM, Shuk E, Romano D, Li Y, Breitbart W, Volandes AE.

J Pain Symptom Manage. 2018 Aug;56(2):169-177.e1. doi: 10.1016/j.jpainsymman.2018.04.009. Epub 2018 May 2.

PMID:
29729347
8.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM.

Lancet Oncol. 2018 Mar;19(3):e151-e160. doi: 10.1016/S1470-2045(18)30098-6. Review.

PMID:
29508762
9.

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.

Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, Sama A, Greeno E, Yu KH, Verslype C, Dawkins F, Walker C, Clark J, O'Reilly EM.

Invest New Drugs. 2018 Aug;36(4):683-695. doi: 10.1007/s10637-018-0580-2. Epub 2018 Mar 6.

PMID:
29508247
10.

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, Kaufmann E, Ravichandran V, Mukherjee S, Berger MF, Hyman DM, Klimstra DS, Abou-Alfa GK, Tjan C, Covington C, Maynard H, Allen PJ, Askan G, Leach SD, Iacobuzio-Donahue CA, Robson ME, Offit K, Stadler ZK, O'Reilly EM.

J Natl Cancer Inst. 2018 Feb 28. doi: 10.1093/jnci/djy024. [Epub ahead of print]

PMID:
29506128
11.

Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?

Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian Y, Abou-Alfa GK, O'Reilly EM.

Clin Colorectal Cancer. 2018 Jun;17(2):e315-e321. doi: 10.1016/j.clcc.2018.01.009. Epub 2018 Feb 7.

PMID:
29496399
12.

Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma.

Mier-Hicks A, Raj M, Do RK, Yu KH, Lowery MA, Varghese A, O'Reilly EM.

Clin Colorectal Cancer. 2018 Jun;17(2):121-128. doi: 10.1016/j.clcc.2018.01.008. Epub 2018 Jan 31.

PMID:
29477452
13.

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA Jr, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM.

Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. doi: 10.1158/1078-0432.CCR-17-3099. Epub 2018 Jan 24.

PMID:
29367431
14.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.

Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.

PMID:
29338080
15.

Preface for Special Edition Pancreas Cancer.

O'Reilly EM, Zheng L.

Chin Clin Oncol. 2017 Dec;6(6):57. doi: 10.21037/cco.2017.12.03. No abstract available.

16.

Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review.

Hicks AM, DeRosa A, Raj M, Do R, Yu KH, Lowery MA, Varghese A, O'Reilly EM.

Clin Colorectal Cancer. 2018 Jun;17(2):e207-e216. doi: 10.1016/j.clcc.2017.12.001. Epub 2017 Dec 12. Review.

PMID:
29306522
17.

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.

Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

PMID:
29295881
18.

Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?

Krantz BA, O'Reilly EM.

Clin Cancer Res. 2018 May 15;24(10):2241-2250. doi: 10.1158/1078-0432.CCR-16-3169. Epub 2017 Dec 21. Review.

PMID:
29269376
19.

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.

Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.

PMID:
29223478
20.

Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients.

Chakraborty J, Langdon-Embry L, Cunanan KM, Escalon JG, Allen PJ, Lowery MA, O'Reilly EM, Gönen M, Do RG, Simpson AL.

PLoS One. 2017 Dec 7;12(12):e0188022. doi: 10.1371/journal.pone.0188022. eCollection 2017.

21.

Ablative Radiotherapy Doses for Locally Advanced: Pancreatic Cancer (LAPC).

Crane CH, O'Reilly EM.

Cancer J. 2017 Nov/Dec;23(6):350-354. doi: 10.1097/PPO.0000000000000292. Review.

PMID:
29189331
22.

Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy.

Jordan EJ, Basturk O, Shia J, Klimstra DS, Alago W, D'Angelica MI, Abou-Alfa GK, O'Reilly EM, Lowery MA.

J Gastrointest Oncol. 2017 Oct;8(5):E65-E72. doi: 10.21037/jgo.2017.06.21.

23.

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.

O'Reilly EM, Roach J, Miller P, Yu KH, Tjan C, Rosano M, Krause S, Avery W, Wolf J, Flaherty K, Nix D, Ryan DP.

Oncologist. 2017 Dec;22(12):1429-e139. doi: 10.1634/theoncologist.2017-0472. Epub 2017 Nov 20.

24.

Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.

Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, Bahary N, Are C.

World J Surg Oncol. 2017 Oct 10;15(1):183. doi: 10.1186/s12957-017-1240-2. Review.

25.

Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?

Sahin IH, Askan G, Hu ZI, O'Reilly EM.

Ann Oncol. 2017 Dec 1;28(12):2950-2961. doi: 10.1093/annonc/mdx503. Review.

PMID:
28945842
26.

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.

Khorana AA, Vadhan-Raj S, Kuderer NM, Wun T, Liebman H, Soff G, Belani C, O'Reilly EM, McBane R, Eikelboom J, Damaraju CV, Beyers K, Dietrich F, Kakkar AK, Riess H, Peixoto RD, Lyman GH.

Thromb Haemost. 2017 Nov 1;117(11):2135-2145. doi: 10.1160/TH17-03-0171. Epub 2017 Sep 21.

27.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.

JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137.

28.

Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies.

Chiaravalli M, Reni M, O'Reilly EM.

Cancer Treat Rev. 2017 Nov;60:32-43. doi: 10.1016/j.ctrv.2017.08.007. Epub 2017 Aug 23. Review.

PMID:
28869888
29.

A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.

Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, Glassman DC, Covington CM, Brenner R, Hollywood E, Barba A, Johnston A, Liu KC, Feng X, Capanu M, Abou-Alfa GK, O'Reilly EM.

Cancer. 2017 Dec 1;123(23):4556-4565. doi: 10.1002/cncr.30897. Epub 2017 Aug 18.

PMID:
28832976
30.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
31.

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.

Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, Leach T, Herbst B, Askan G, Maynard H, Glassman D, Covington C, Schultz N, Abou-Alfa GK, Harding JJ, Klimstra DS, Hechtman JF, Hyman DM, Allen PJ, Jarnagin WR, Balachandran VP, Varghese AM, Schattner MA, Yu KH, Saltz LB, Solit DB, Iacobuzio-Donahue CA, Leach SD, O'Reilly EM.

Clin Cancer Res. 2017 Oct 15;23(20):6094-6100. doi: 10.1158/1078-0432.CCR-17-0899. Epub 2017 Jul 28.

PMID:
28754816
32.

An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses.

Vasan N, Braghiroli MI, Shoushtari AN, Do RKG, Edelweiss M, Shamseddine A, Faraj W, Mukherji D, Haydar A, Olayan A, Sabatin F, Assi R, El Dika I, Saltz LB, Abou-Alfa GK, O'Reilly EM.

J Gastrointest Oncol. 2017 Jun;8(3):596-602. doi: 10.21037/jgo.2017.01.21. No abstract available.

33.

Pancreas adenocarcinoma: novel therapeutics.

Krantz BA, Yu KH, O'Reilly EM.

Chin Clin Oncol. 2017 Jun;6(3):30. doi: 10.21037/cco.2017.06.14.

34.

Preface: pancreas adenocarcinoma.

O'Reilly EM, Zheng L.

Chin Clin Oncol. 2017 Jun;6(3):23. doi: 10.21037/cco.2017.06.22. No abstract available.

35.

Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.

Park JJ, Hajj C, Reyngold M, Shi W, Zhang Z, Cuaron JJ, Crane CH, O'Reilly EM, Lowery MA, Yu KH, Goodman KA, Wu AJ.

Acta Oncol. 2017 Dec;56(12):1746-1753. doi: 10.1080/0284186X.2017.1342863. Epub 2017 Jun 29.

PMID:
28661823
36.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C.

JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.

37.

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.

Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S.

Br J Cancer. 2017 Mar 14;116(6):697-702. doi: 10.1038/bjc.2017.19. Epub 2017 Feb 9.

38.

Management of Metastatic Pancreatic Adenocarcinoma.

Cheema AR, O'Reilly EM.

Surg Clin North Am. 2016 Dec;96(6):1391-1414. doi: 10.1016/j.suc.2016.07.011. Review.

PMID:
27865284
39.

Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection.

Huguet F, Hajj C, Winston CB, Shi W, Zhang Z, Wu AJ, O'Reilly EM, Reidy DL, Allen P, Goodman KA.

Acta Oncol. 2017 Mar;56(3):384-390. doi: 10.1080/0284186X.2016.1245862. Epub 2016 Oct 31.

40.

Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?

Teo MY, O'Reilly EM.

J Gastrointest Oncol. 2016 Oct;7(5):738-749. Review.

41.

Current management and future directions in metastatic pancreatic adenocarcinoma.

Varghese AM, Lowery MA, Yu KH, O'Reilly EM.

Cancer. 2016 Dec 15;122(24):3765-3775. doi: 10.1002/cncr.30342. Epub 2016 Sep 20. Review.

42.

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.

Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, Mills GB, O'Reilly EM, Knudsen ES.

Cell Rep. 2016 Aug 16;16(7):2017-31. doi: 10.1016/j.celrep.2016.07.023. Epub 2016 Aug 4.

43.

Development of an advance care planning paradigm for advanced cancer: person-centered oncologic care and choices (P-COCC).

Epstein AS, O'Reilly EM, Shuk E, Breitbart W, Shah MA, Ly M, Tayler R, Volandes AE.

Psychooncology. 2017 Jun;26(6):866-869. doi: 10.1002/pon.4167. Epub 2016 Jun 7. No abstract available.

44.

Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.

Hicks AM, Chou J, Capanu M, Lowery MA, Yu KH, O'Reilly EM.

Clin Colorectal Cancer. 2016 Dec;15(4):360-368. doi: 10.1016/j.clcc.2016.04.014. Epub 2016 May 7.

45.

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D.

J Clin Oncol. 2016 Aug 10;34(23):2784-96. doi: 10.1200/JCO.2016.67.1412. Epub 2016 May 31. Review.

46.

Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer.

Epstein AS, Prigerson HG, O'Reilly EM, Maciejewski PK.

J Clin Oncol. 2016 Jul 10;34(20):2398-403. doi: 10.1200/JCO.2015.63.6696. Epub 2016 May 23.

47.

Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.

Li D, O'Reilly EM.

Surg Oncol Clin N Am. 2016 Apr;25(2):311-26. doi: 10.1016/j.soc.2015.11.010. Epub 2016 Feb 17. Review.

PMID:
27013366
48.

Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.

Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM.

Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26. Review.

49.

ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy.

O'Neill CB, Atoria CL, O'Reilly EM, Henman MC, Bach PB, Elkin EB, O'Neill CB, Atoria CL, O'Reilly EM, Henman MC, Bach PB, Elkin EB.

J Oncol Pract. 2016 Feb;12(2):151-2; e138-48. doi: 10.1200/JOP.2015.004812.

50.

Early Detection and Treatment Opportunities in Pancreatic Adenocarcinoma.

O'Reilly EM.

J Oncol Pract. 2016 Jan;12(1):31-2. doi: 10.1200/JOP.2015.009985. No abstract available.

PMID:
26759463

Supplemental Content

Loading ...
Support Center